Navigation Links
Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
Date:6/10/2009

ion is anticipated to jump to $85 billion in the next two decades. As a result, Medicare costs are anticipated to soar 500%, from $5 billion to $30 billion. As the stakes to treat HCV are high, the competition for new drugs is intense with more than sixty treatment candidates reported to be in development. As we target the use of our Hemopurifier(R) as a drug enhancement device in HCV care, we are positioned to improve treatment outcomes as an adjunct to both SOC therapy and new drug candidates that evolve to challenge SOC therapy in the marketplace.

Significant challenges exist for drugs seeking to supplant SOC therapy, as new candidates must demonstrate substantially greater patient benefit in order for the medical community to consider discontinuing administration of the SOC treatment regimen. As an example, Albuferon, an HCV treatment candidate from Human Genome Sciences (HGSI), recently demonstrated phase III treatment outcomes comparable to SOC therapy with half the number of required injections. As a result, the value of HGSI shares was reduced by 57% the day the study data was released. I can't help but wonder how Albuferon might have performed in combination with our Hemopurifier(R)? Regardless, a drug candidate wishing to supplant SOC therapy in the market will need to Bob Beamon (surpassed world long jump record by almost two feet at the 1968 Olympics) beyond the capabilities of SOC therapy.

For this reason, the primary strategy for most HCV drug candidates is to incrementally improve treatment outcomes as an adjunct to SOC therapy. The challenge facing these candidates is the effect of stacking new drug toxicity on top of established SOC toxicity, which is known to trigger fatigue, bone marrow suppression, anemia and neuropsychiatric effects. Many patients fail SOC therapy because they are unable to endure the toxicity of the 24-48 week regimen on its own. Based on clinical data, Telaprevir, a 3x-day o
'/>"/>

SOURCE Aethlon Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Aethlon Medical Announces CEO Interview and Corporate Presentation Available Online
2. Aethlon Medical Announces Engagement of RedChip Companies to Initiate Investor and Media Relations Programs
3. Aethlon Medical Confirms Hemopurifier(R) Is a Treatment Candidate Against Swine Flu Virus
4. Aethlon Medical Discloses New HIV/AIDS Treatment Data
5. MSU engineering team designs innovative medical device
6. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
7. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
8. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
9. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
10. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
11. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... It,s estimated that as many as 10 million older ... of loneliness and isolation. , However, new research ... retired older Americans for six years found that ... of depression by more than 30 percent. , "That,s ... State University professor of telecommunication, information studies and media ...
(Date:4/17/2014)... from Boston University School of Medicine (BUSM) have ... consumption in an experimental model. The findings, reported ... Alcohol Abuse , may lead to more effective ... is one of the leading causes of illness ... negative economic impact by limiting the productivity of ...
(Date:4/17/2014)... by Cesar A. Arias, M.D., Ph.D., at The University ... identified a new superbug that caused a bloodstream infection ... April 17 issue of The New England Journal ... of a class of highly-resistant bacteria known as methicillin-resistant ... major cause of hospital and community-associated infections. The superbug ...
(Date:4/17/2014)... therapy improves general blood flow and alleviates muscle ... researchers at the University of Illinois at Chicago. ... print in the Archives of Physical Medicine ... vascular function in people who had not exercised, ... of their level of physical activity. , Improved ...
(Date:4/17/2014)... 17, 2014 Giving patients adrenaline after they suffer a ... their prospects of surviving long-term, according to new research ... of patients who have a cardiac arrest get adrenaline, ... arrest for decades," said Dr. Steve Lin, an emergency ... despite advances in medical treatment, long-term survival rates of ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:New MRSA superbug emerges in Brazil 2Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2
... with Rare Hair Loss Disease, SCARBOROUGH, N.Y., Feb. ... wants you to notice. "February is the perfect time ... auto-immune skin disease,alopecia areata," encourages Chassin, founder and president ... are healthier when,women and the people who love them ...
... healthy people, both sleepiness and vigilance show a relationship ... core body temperature is high during the daytime, skin ... Conversely, when core body temperature is low at night ... sleep. Among those suffering from narcolepsy, however, direct ...
... NJ Business Leaders Learn How Their Employee Health ... 31 Business owners and human,resource executives grappling ... competitive and cost effective found out how their ... at Embassy Suites,Parsippany. Scott Rappoport, a 25-year veteran ...
... is enthused about Part D,s success, but critics say ... -- The three-year-old Medicare Part D drug program is ... costs for the program fall, U.S. health officials announced ... considerably lower than originally projections, enrollment continues to rise ...
... Jan. 31 Today Genghis Grill will launch ... 20 locations nationwide -- Asian,Chili Scallop Bowl. The ... with a,variety of fresh heart-healthy ingredients from Khan,s ... Three more recipes are scheduled to,launch nationwide starting ...
... director of the National Alliance on Mental Illness ... circus and reckless speculation has surrounded events in ... family. Professional ethics,require that mental health professionals who ... diagnose them. A person,s treatment and recovery,from any ...
Cached Medicine News:Health News:Bald Valentine Offers Loving Tips in Maryland 2Health News:Changes in narcoleptics' skin, core body temperatures affect their vigilance and sleepiness 2Health News:Changes in narcoleptics' skin, core body temperatures affect their vigilance and sleepiness 3Health News:Key to Attracting and Retaining Quality Employees: Benefits 2Health News:Key to Attracting and Retaining Quality Employees: Benefits 3Health News:Medicare's Drug Program Enrollment Up, Costs Down 2Health News:Medicare's Drug Program Enrollment Up, Costs Down 3Health News:Genghis Grill Offers Recipes Featuring Heart Healthy Dining Options 2Health News:Britney Spears: Let's Talk About All of Us 2
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... developing its Symphony® CGM System as a non-invasive, wireless ... F. Doman , Executive Chairman and Interim CEO of ... Markets, Tenth Annual Equity Conference. Mr. ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... from MedImmune, PRINCETON, N.J., Aug. 12 ... its partner MedImmune, Inc. has,initiated a Phase 2A ... of systemic lupus erythematosus (SLE or lupus).,MEDI-545 is ... Human,Antibody Development System(R). Under the terms of the ...
... Therapeutics, Inc., a,privately held immunotherapeutics discovery and ... of novel immunotherapies for the,treatment of cancer, ... agreements with the Memorial Sloan-Kettering Cancer Center,s,Sloan-Kettering ... http://www.newscom.com/cgi-bin/prnh/20080812/LATU515LOGO ), The first license ...
Cached Medicine Technology:Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 2Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 3Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 4MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research 2
The Bard Ellik Bladder Evacuator is designed for ease of maneuverability during the removal of tissue sections during transurethral prostatectomy, TURPs, bladder biopsy, etc....
Inquire...
... BT table comes in two modelsthe BT4, ... the BT5, which offers five. With the ... adjust to suit your needs. Both ... controls, side rails, ankle/foot supports, adjustable arm ...
UROSKOP Access, the dedicated urodiagnostic table with truly unrestricted patient access optimizes nearly all diagnostic and interventional procedures....
Medicine Products: